Looking at the CYDY MCRC abstract. I noticed the first 5 patients had zero CTC's and decreasing CAML's. Maybe not significant this early but cant hurt. Thought I might as well post it (since I looked it up) if anyone wants to see it. And keep up with the possible updated poster data
CTCs at baseline: median (range)* 0 (0-2)
CTCs at follow-up: median (range)* 0 (0-4)
CAMLs at baseline: median (range)* 47 (1-67)
CAMLs at follow-up: median (range)* 31 (1-87)
* 5 patients with both baseline and Week 1 data
From a Creatv bio MBC study
https://static1.squarespace.com/static/5bbbe3...+final.pdf
The below statement is discussing MBC so may not correlate
"Combined Prognostic Value: Patients with decreasing CAMLs and the absence of CTCs after treatment show the best survival outcomes, with improvements in both median PFS (e.g., 15.0 months) and median OS (e.g., 18.8 months)."
CTCs were identified in 35% (n=35/101) of pts at BL & 26% (n=26/101) at T1.
A single CTC at T1 was highly prognostic for worse PFS HR=6.5, p<0.0001 and OS HR=5.2, p=0.00188 (Table 1).
CAMLs were found in 93% (n=94/11) of pts as BL and 86% (n=87/101) of pts at T1.
CAML decreases (ie size/number) were significantly prognostic for improved PFS (HR=2.8, p=0.00029 and OS HR=2.6,
p=0.01895 when CTCs were
absent (Table 1).
Pts with ≥1 CTC at T1 (n=26) had median PFS=2.4 and mOS=4.7months.
Pts without CTCs plus increasing CAMLs (n=36) had mPFS=5.9 and mOS=14.1 months.
Pts without CTCs plus decreasing CAMLs (n=39) had mPFS=15.0 and mOS=18.8 mos..
CTCs at baseline: median (range)* 0 (0-2)
CTCs at follow-up: median (range)* 0 (0-4)
CAMLs at baseline: median (range)* 47 (1-67)
CAMLs at follow-up: median (range)* 31 (1-87)
* 5 patients with both baseline and Week 1 data
From a Creatv bio MBC study
https://static1.squarespace.com/static/5bbbe3...+final.pdf
The below statement is discussing MBC so may not correlate
"Combined Prognostic Value: Patients with decreasing CAMLs and the absence of CTCs after treatment show the best survival outcomes, with improvements in both median PFS (e.g., 15.0 months) and median OS (e.g., 18.8 months)."
CTCs were identified in 35% (n=35/101) of pts at BL & 26% (n=26/101) at T1.
A single CTC at T1 was highly prognostic for worse PFS HR=6.5, p<0.0001 and OS HR=5.2, p=0.00188 (Table 1).
CAMLs were found in 93% (n=94/11) of pts as BL and 86% (n=87/101) of pts at T1.
CAML decreases (ie size/number) were significantly prognostic for improved PFS (HR=2.8, p=0.00029 and OS HR=2.6,
p=0.01895 when CTCs were
absent (Table 1).
Pts with ≥1 CTC at T1 (n=26) had median PFS=2.4 and mOS=4.7months.
Pts without CTCs plus increasing CAMLs (n=36) had mPFS=5.9 and mOS=14.1 months.
Pts without CTCs plus decreasing CAMLs (n=39) had mPFS=15.0 and mOS=18.8 mos..
12
